Abstract
Background and Aim: Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus (HCV) infection and cirrhosis, although it can also be observed in patients without cirrhosis by a virus-mediated phenomenon. This study assessed the prevalence, characteristics, and outcomes of antiviral therapy in patients with chronic HCV infection and thrombocytopenia not associated with cirrhosis. Methods: The study included 1268 patients with HCV infection and thrombocytopenia enrolled in the phase 3 ENABLE studies that assessed the impact of eltrombopag on achieving a sustained virologic response to pegylated interferon and ribavirin. The study population was subdivided according to baseline FibroSURE test results into patients with non-cirrhosis (FibroSURE
Original language | English |
---|---|
Pages (from-to) | 1301-1308 |
Number of pages | 8 |
Journal | Journal of Gastroenterology and Hepatology |
Volume | 30 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 1 2015 |
Keywords
- Cirrhosis
- Eltrombopag
- Hepatitis C virus
- Interferon
- Platelets
ASJC Scopus subject areas
- Gastroenterology
- Hepatology